praescia
Products

Two products. One intelligence architecture.

The same seven-stage spine. The same GxP compliance shell. The same “Atlas Inside” density network. Two domain leaves — one for biopharma manufacturing, one for the genetics industry.

Biopharma manufacturing intelligence

Praescia

Know the batch before it turns.

Design-partner phase · evidence gate open

Praescia reads process historians, in-line sensors, and MES data to detect batch deviation and line constraint before the outcome is fixed. A bioreactor batch that fails its release assay is a post-mortem. Praescia turns that into a foreseen, explained, documented catch.

What it detects

  • Golden-batch deviation onset — hours before it’s obvious
  • Early titer / yield / OOS-risk signal — called pre-harvest
  • Fill-finish line bottleneck & EM excursion
  • Tech transfer drift at the first new-site runs
  • Cold-chain excursion risk in transit
  • Cross-site fleet performance gaps (density tier)

Who it serves

  • CDMOs — density economics: one validated model, many lines and sites
  • Biotech / pharma MSAT — batch-loss avoidance and tech transfer
  • Cell & gene therapy — highest-value batches; one patient, one dose
  • Fill-finish & drug product — line constraint intelligence
  • Bioreactor / PAT OEMs — intelligence inside, Atlas Inside mark

Compliance

21 CFR Part 11 · EU Annex 11 · GAMP 5 · ALCOA+ — built in, not bolted on.

Engine

Atlas PC (Production Constraint) + Atlas OI (Industrial Operations) + GxP compliance shell, coupled via atlas_compose.

Genetics industry intelligence

Praescigenics

Catch the failing run before it fails.

Gate-1a proven on real ONT telemetry · Gate-1b open

Praescigenics applies the Praescia spine to the genetics industry: sequencing-run QC (a run is a monitored batch — Q-scores, cluster/pore density, reagent state, error rate) and regulated genomics manufacturing (vector, plasmid, cell/gene therapy). A DNA sequencer is a biosensor at scale. The same foreknowledge applies.

What it detects

  • Sequencing-run quality excursion onset — before run failure or rework
  • Q-score drift (%≥Q30, error rate) departing the golden reference
  • Cluster density / pore occupancy anomaly (overload & underload)
  • Reagent & flowcell lot excursion — surfaced across every run using that lot
  • Vector / plasmid / cell-therapy manufacturing deviation (via Praescia leaf)
  • Cross-lab lot-level signals (density tier — federated telemetry, not genomes)

Who it serves

  • Sequencing labs (CLIA / CAP) — run-QC intelligence, instrument state
  • Genomics CDMOs & manufacturers — vector, plasmid, cell-therapy lines
  • Instrument OEMs — Illumina, Oxford Nanopore, PacBio OEM embed path
  • Bioinformatics & LIMS platforms — intelligence layer above the pipeline

Compliance

21 CFR Part 11 · GAMP 5 · ALCOA+ (manufacturing, inherited from Praescia). CLIA / CAP lab context (sequencing); FDA SaMD decision-support posture maintained throughout.

Engine

Praescia spine vendored (praescia_core + atlas_compose) + genetics leaf (praescigenics_core). Platforms: Illumina NovaSeq / NextSeq / MiSeq · Oxford Nanopore · PacBio Revio · Element.

How they compare

Dimension Praescia Praescigenics
Domain Biopharma manufacturing (bioreactor, fill-finish, drug product) Genetics industry (sequencing labs, genomics manufacturing)
The “batch” A bioreactor run or fill-finish production batch A sequencing run (Illumina / ONT / PacBio) or a vector/plasmid manufacturing batch
Key signals pH, DO, temperature, biomass, feed rate, metabolites, EM, WFI, HVAC %≥Q30, error rate, cluster density / pore occupancy, reagent / flowcell lot state
Primary buyers CDMOs, biotech MSAT, CGT manufacturers, fill-finish operators Sequencing labs (CLIA/CAP), genomics CDMOs, instrument OEMs
Regulatory frame 21 CFR Part 11 · EU Annex 11 · GAMP 5 · ALCOA+ 21 CFR Part 11 / GAMP 5 (manufacturing) + CLIA / CAP (clinical lab); FDA SaMD posture
Density moat Cross-site golden-trajectory benchmarking; CDMO fleet intel Federated QC telemetry (not genomes); reagent/flowcell lot-level cross-lab signals
Evidence status Design-partner phase; evidence gate open Gate-1a proven on real ONT telemetry; Gate-1b (labeled) open
Core engine Atlas PC + Atlas OI + GxP compliance shell Praescia spine vendored + praescigenics_core genetics leaf
Posture Insight-only throughout — observe, predict, advise; never actuate on equipment, process, or instrument

The shared foundation

Both products run on the same proven architecture. The spine is the invariant. The domain vocabulary is the skin.

Shared

Seven-stage spine

OBSERVE → NORMALIZE → DETECT_STATE → DETECT_TRANSITION → ESTIMATE_OUTCOME → RECOMMEND → VALIDATE. One deterministic pipeline, proven across four production verticals.

Shared

GxP compliance shell

21 CFR Part 11 audit trail, e-signature manifests, ALCOA+ data-integrity gate at every I/O boundary. Ships with both products. Not a professional-services engagement.

Shared

“Atlas Inside” density network

The cross-asset, cross-site density layer. Both products publish into it. Both compound in value as asset count grows. The moat is the same architecture, pointed at two industries.

Shared

Insight-only posture

Neither product actuates on process equipment, MES recipes, or sequencing instruments. Every advisory requires human disposition. Permanent — not a phase.

Shared

atlas_compose coupler

The same composable coupler and engine manifest system under both products. New platform adapters and capability components snap in as plugins — not forks.

Shared

Explainable advisories

Named signal drivers. Reason codes. Deterministic replay. Every advisory defensible in an audit, a deviation investigation, or a CLIA inspector review.

Naming architecture

LayerNameRole
Platform / engine classAtlasThe proven composable spine powering both products
Ingredient markAtlas InsideNetwork layer · interoperability · density moat
Manufacturing productPraesciaBiopharma manufacturing intelligence — what the market buys
Genetics productPraescigenicsGenetics-industry intelligence — Praescia-family specialization
Shared promiseforesightThe story both products tell — we foresee the batch / the run

Design-partner program — both products

Both Praescia and Praescigenics are in active design-partner search. If you run bioreactors, fill-finish lines, sequencing instruments, or genomics manufacturing with real process data, we want to talk.

Apply for the program About the company